MRD as Biomarker for Response to Donor Lymphocyte Infusion after Allogeneic Hematopoietic Cell Transplantation in Patients with AML

Simple Summary Donor lymphocyte infusions (DLIs) are immune cells of the donor. They can potentially directly target leukemic cells. Thus, DLIs can be given to acute myeloid leukemia (AML) patients after allogeneic hematopoietic cell transplantation (alloHCT) in order to prevent or treat relapse. Measurable residual disease (MRD) describes very low levels of disease. Currently, it is still not well described how we can use MRD assessment for predicting response and outcome after DLI. This is a retrospective study looking at 76 AML patients receiving DLI treatment. MRD was evaluated prior to DLI treatment as well as 30 and 90 days after DLI. It was observed that within 90 days after DLI treatment, 73% of MRD+ patients converted to MRD−. Furthermore, MRD and remission status at the time of DLI were highly prognostic for the outcome (both for the relapse rate and also for relapse-free survival). Abstract Donor lymphocyte infusions (DLIs) can directly target leukemic cells through a graft-versus-leukemia effect and play a key role in the prevention and management of relapse after allogeneic hematopoietic cell transplantation (alloHCT). Predictors of response to DLIs are not well established. We evaluated measurable residual disease (MRD) before, 30 and 90 days after DLI treatment as biomarkers of response. MRD was assessed by next-generation sequencing in 76 DLI-treated acute myeloid leukemia patients. MRD status before DLI treatment was independently prognostic for event-free survival (EFS, p < 0.001) and overall survival (OS, p < 0.001). Within 90 days of DLI treatment, 73% of MRD+ patients converted to MRD− and 32% of patients without remission achieved remission. MRD status 90 days after DLI treatment was independently prognostic for the cumulative incidence of relapse (CIR, p = 0.011) and relapse-free survival (RFS, p = 0.001), but not for OS. To evaluate the role of DLI treatment in MRD− patients, 23 MRD− patients who received DLIs were compared with a control cohort of 68 MRD− patients not receiving DLIs. RFS (p = 0.23) and OS (p = 0.48) were similar between the two cohorts. In conclusion, MRD is prognostic before (EFS, OS) and after (CIR, RFS) DLI treatment and may help in the selection of patients who benefit most from DLIs.

[1]  C. Hourigan,et al.  Measurable residual disease in patients undergoing allogeneic transplant for acute myeloid leukemia. , 2023, Best practice & research. Clinical haematology.

[2]  B. Ebert,et al.  Diagnosis and Management of AML in Adults: 2022 ELN Recommendations from an International Expert Panel. , 2022, Blood.

[3]  S. Kako,et al.  Donor lymphocyte infusion after haploidentical hematopoietic stem cell transplantation for acute myeloid leukemia , 2022, Annals of Hematology.

[4]  G. Milone,et al.  Prevention and Treatment of Acute Myeloid Leukemia Relapse after Hematopoietic Stem Cell Transplantation: The State of the Art and Future Perspectives , 2022, Journal of clinical medicine.

[5]  J. Esteve,et al.  Long-term results and GvHD after prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia , 2021, Bone Marrow Transplantation.

[6]  K. Döhner,et al.  2021 Update Measurable Residual Disease in Acute Myeloid Leukemia: European LeukemiaNet Working Party Consensus Document. , 2021, Blood.

[7]  L. Bullinger,et al.  Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutations. , 2021, Blood advances.

[8]  M. Lübbert,et al.  Donor lymphocyte infusions after first allogeneic hematopoietic stem-cell transplantation in adults with acute myeloid leukemia: a single-center landmark analysis , 2021, Annals of Hematology.

[9]  H. Deeg,et al.  Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  P. Vyas,et al.  The Graft-Versus-Leukemia Effect in AML , 2019, Front. Oncol..

[11]  J. Bourhis,et al.  Donor Lymphocyte Infusions After Allogeneic Transplantation: A Single-Center Experience. , 2019, Clinical lymphoma, myeloma & leukemia.

[12]  R. Maziarz,et al.  Next‐generation sequencing‐defined minimal residual disease before stem cell transplantation predicts acute myeloid leukemia relapse , 2019, American journal of hematology.

[13]  J. Esteve,et al.  Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation in acute leukaemia – a matched pair analysis by the Acute Leukaemia Working Party of EBMT , 2018, British journal of haematology.

[14]  Michael Stadler,et al.  Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML. , 2018, Blood.

[15]  Marc S. Tyndel,et al.  Next-generation sequencing-based posttransplant monitoring of acute myeloid leukemia identifies patients at high risk of relapse. , 2018, Blood.

[16]  Markus G. Manz,et al.  Molecular Minimal Residual Disease in Acute Myeloid Leukemia , 2018, The New England journal of medicine.

[17]  R. Geffers,et al.  Individual outcome prediction for myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia from MDS after allogeneic hematopoietic cell transplantation , 2017, Annals of Hematology.

[18]  F. Bosch,et al.  Donor lymphocyte infusions in AML and MDS: Enhancing the graft-versus-leukemia effect. , 2017, Experimental hematology.

[19]  D. Marin,et al.  Early Post-Transplant Minimal Residual Disease Assessment Improves Risk Stratification in Acute Myeloid Leukemia. , 2017, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[20]  Bob Löwenberg,et al.  Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. , 2017, Blood.

[21]  Inigo Martincorena,et al.  Precision oncology for acute myeloid leukemia using a knowledge bank approach , 2017, Nature Genetics.

[22]  M. Schmid,et al.  ISCN 2016: An International System for Human Cytogenomic Nomenclature (2016) , 2016 .

[23]  Nicola D. Roberts,et al.  Genomic Classification and Prognosis in Acute Myeloid Leukemia. , 2016, The New England journal of medicine.

[24]  L. Castagna,et al.  Donor lymphocyte infusion after allogeneic stem cell transplantation. , 2016, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[25]  J. Magenau,et al.  Advances in understanding the pathogenesis of graft‐versus‐host disease , 2016, British journal of haematology.

[26]  R. Feinman,et al.  Strategies for the identification of T cell-recognized tumor antigens in hematological malignancies for improved graft-versus-tumor responses after allogeneic blood and marrow transplantation. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[27]  Y. Kanda,et al.  Donor lymphocyte infusion for the treatment of relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: a retrospective analysis by the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[28]  He Huang,et al.  Superiority of preemptive donor lymphocyte infusion based on minimal residual disease in acute leukemia patients after allogeneic hematopoietic stem cell transplantation , 2014, Transfusion.

[29]  A. Bashey,et al.  Preemptive DLI without withdrawal of immunosuppression to promote complete donor T-cell chimerism results in favorable outcomes for high-risk older recipients of alemtuzumab-containing reduced-intensity unrelated donor allogeneic transplant: a prospective phase II trial , 2014, Bone Marrow Transplantation.

[30]  H. Veelken,et al.  Intentional donor lymphocyte-induced limited acute graft-versus-host disease is essential for long-term survival of relapsed acute myeloid leukemia after allogeneic stem cell transplantation , 2014, Haematologica.

[31]  M. Bar,et al.  Donor lymphocyte infusion for relapsed hematological malignancies after allogeneic hematopoietic cell transplantation: prognostic relevance of the initial CD3+ T cell dose. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[32]  Ya-Zhen Qin,et al.  Combined use of WT1 and flow cytometry monitoring can promote sensitivity of predicting relapse after allogeneic HSCT without affecting specificity , 2013, Annals of Hematology.

[33]  G. Mufti,et al.  Outcome of donor lymphocyte infusion after T cell-depleted allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndromes. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[34]  Yan-rong Liu,et al.  Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation. , 2012, Blood.

[35]  N. Kröger,et al.  Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation. , 2012, Blood.

[36]  H. Kolb.  Graft-versus-leukemia effects of transplantation and donor lymphocytes. , 2008, Blood.

[37]  B. Dörken,et al.  A pilot study of prophylactic donor lymphocyte infusions to prevent relapse in adult acute lymphoblastic leukemias after allogeneic hematopoietic stem cell transplantation , 2008, Bone Marrow Transplantation.

[38]  M. Labopin,et al.  Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  D. Porter,et al.  Donor leukocyte infusions in myeloid malignancies: new strategies. , 2006, Best practice & research. Clinical haematology.

[40]  Je-Hwan Lee,et al.  Treatment of relapsed acute myeloid leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: a high incidence of isolated extramedullary relapse , 2004, Leukemia.

[41]  S. Saidman,et al.  Impact of prophylactic donor leukocyte infusions on mixed chimerism, graft-versus-host disease, and antitumor response in patients with advanced hematologic malignancies treated with nonmyeloablative conditioning and allogeneic bone marrow transplantation. , 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[42]  Ion Gresser,et al.  Type I interferons produced by dendritic cells promote their phenotypic and functional activation. , 2002, Blood.

[43]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[44]  M. Heuser,et al.  2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party , 2021 .

[45]  W. Wilmanns,et al.  Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. , 1990, Blood.

[46]  R. Gray.  A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk , 1988 .